Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, Immune cells in cancer, and Cutaneous Melanoma Detection and Management.
Abstract LB-B005: No effect of the time-of-day infusion of adjuvant pembrolizumab in the outcomes of patients with resectable melanoma in the NCI/SWOG trial S1404
Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)—Final clinical results.
1601O 3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
LBA48 Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial
LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)
Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134.
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Prognostic Gene Expression Profiling in Cutaneous Melanoma
Impact of age‐related T‐cell dynamics on the identification of biomarkers predictive of immunotherapy discontinuation: A prospective cohort study
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials
Skin Cancer Screening: Recommendations for Data-Driven Screening Guidelines and a review of the US Preventive Services Task Force Controversy
The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma
Assessment of the drug interaction potential and single‐ and repeat‐dose pharmacokinetics of the BRAF inhibitor dabrafenib
A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors